Pancragen (20mg) is a synthetic short-chain peptide supplied for controlled laboratory research and analytical evaluation. It is commonly identified by the amino acid sequence Lys-Glu-Asp-Trp, abbreviated KEDW.
Laboratory studies may use Pancragen in pancreatic-derived cellular models to examine peptide identity, molecular interactions, gene-expression-associated markers, and other predefined analytical endpoints. References to pancreatic, metabolic, or endocrine models identify categories of laboratory investigation only and do not indicate therapeutic properties or effects on pancreatic function, glucose regulation, digestion, or metabolism.
Lot-specific analytical documentation is available through the Nordsci Certificate of Analysis Library. Researchers should review the COA associated with the applicable product lot before beginning an experiment.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
Pancragen (20mg) is a synthetic tetrapeptide supplied as a lyophilized research material for controlled laboratory analysis and in vitro experimentation. Pancragen is commonly represented by the amino acid sequence Lys-Glu-Asp-Trp, abbreviated KEDW.
Laboratory research involving Pancragen may examine peptide characterization, analytical identity, stability, molecular interactions, and predefined markers within pancreatic-derived cellular systems. Experimental findings remain limited to the selected model, concentration range, exposure period, controls, and analytical methods.
References to pancreatic tissue, metabolic pathways, endocrine signaling, or digestive systems describe the origin or classification of an experimental model. They do not indicate that Pancragen maintains, restores, protects, or changes pancreatic function or physiological processes in humans or animals.
Pancragen (20mg) – Research Specifications:
| Compound | Pancragen |
| Quantity | 20mg per vial |
| Sequence | Lys-Glu-Asp-Trp (KEDW) |
| Compound Type | Synthetic tetrapeptide research material |
| Form | Lyophilized powder |
| Purity / Identity | Refer to the lot-specific Certificate of Analysis |
| Analytical Documentation | Lot-specific documentation may report HPLC, mass spectrometry, or other applicable analytical results |
| Storage Conditions | Store sealed at −20°C or below and protect from light, heat, and moisture unless otherwise stated in the applicable documentation |
| Research Classification | Laboratory research and analytical use only |
| Restrictions | Not for human or animal consumption or in vivo, diagnostic, therapeutic, food, drug, cosmetic, or dietary-supplement use |
Pancragen is a synthetic short-chain peptide used in controlled laboratory studies involving peptide chemistry, molecular signaling, and pancreatic-derived cellular models. Its four-amino-acid sequence provides researchers with a defined compound for analytical characterization and comparative assay development.
In vitro studies may use Pancragen to examine peptide-associated molecular activity within selected cellular systems. Applicable endpoints can include compound identity, intracellular localization, gene-expression-associated markers, protein-associated measurements, or other assay-specific observations.
Pancreatic-derived cell models can contain different cellular populations and signaling systems. Researchers should identify the specific cell type, molecular target, concentration range, exposure period, analytical method, and acceptance criteria before interpreting a measured response.
References to pancreatic biology, endocrine communication, glucose-associated pathways, or metabolic signaling identify areas of laboratory investigation. They do not indicate effects on blood glucose, insulin, digestion, energy balance, pancreatic health, or any other human or animal outcome.
Important Research Notice: Nordsci research materials are supplied with access to lot-specific analytical documentation. Researchers should consult the applicable Certificate of Analysis for reported identity and purity information.
THIS PRODUCT IS INTENDED EXCLUSIVELY FOR LABORATORY RESEARCH. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR IN VIVO, DIAGNOSTIC, THERAPEUTIC, FOOD, DRUG, COSMETIC, OR DIETARY-SUPPLEMENT USE.
Pancragen may be evaluated in controlled pancreatic-derived cell systems designed to measure predefined molecular or cellular markers. Researchers can compare the test material with untreated, vehicle, or other appropriate control groups.
Results remain specific to the selected in vitro model and should not be interpreted as evidence of an effect on the human or animal pancreas.
Laboratory models may use Pancragen when examining selected markers associated with metabolic signaling pathways. Experimental plans should identify the target marker, reference controls, sampling intervals, analytical platform, and acceptance criteria before testing.
Observed activity in a metabolic-pathway assay does not establish effects on metabolism, blood glucose, insulin, body composition, appetite, or energy balance.
Pancragen may be incorporated into comparative studies involving endocrine-associated or pancreatic-derived cell cultures. Researchers can evaluate assay-specific molecular observations across consistent experimental conditions.
The use of endocrine-associated models identifies the laboratory system. It does not indicate that Pancragen regulates, balances, increases, or decreases hormones in humans or animals.
Researchers may compare Pancragen with untreated controls or other research materials within standardized cell-based assays. Comparative study designs can help distinguish test-material observations from background activity or model-specific variability.
Differences between experimental groups should be interpreted only within the limitations of the selected model, controls, methods, and analytical endpoints.
Pancragen (20mg) should be handled only by qualified laboratory personnel using established procedures for synthetic peptide research materials. Laboratories should document product receipt, lot identification, storage conditions, sample allocation, testing methods, and disposal.
No reconstitution volume, diluent selection, concentration, dosing, injection, administration, or in vivo application guidance is provided.
Protocol Design Considerations:
Note: This information is provided exclusively as a laboratory research reference. All work should be conducted by qualified personnel in appropriately equipped facilities and in accordance with applicable institutional requirements.
Lot-specific Certificates of Analysis provide analytical information associated with the applicable Pancragen product lot. Documentation may include identity, purity, testing methodology, and other reported analytical results.
Researchers should confirm that the lot number on the vial corresponds with the lot number shown on the applicable COA. Analytical findings apply only to the tested lot and should not be interpreted as evidence of clinical safety, effectiveness, or approval for human or veterinary use.
Nordsci Peptides supplies Pancragen (20mg) as a laboratory research material with access to lot-specific analytical documentation. Laboratories should evaluate compound identity, reported analytical results, storage requirements, batch traceability, and institutional procurement standards before use.
IMPORTANT: Pancragen (20mg) is sold exclusively for laboratory research and analytical use. It is not a drug, food, dietary supplement, cosmetic, or therapeutic product. It is not approved for human or veterinary use and must not be used for consumption, diagnosis, treatment, prevention, compounding, or any in vivo procedure.
